Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Mazdutide: Evidence Summary
Evidence summary for Mazdutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Mazdutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Type 2 Diabetes (glycemic control) | Tier A | 5 | Multiple Phase 2/3 RCTs; NMPA approved September 2025 |
| Obesity / weight management | Tier B | 3 | Phase 3 GLORY-2 showed 20.1% weight loss; not yet approved for this indication |
References (4)
- Efficacy and safety of mazdutide in Chinese adults with obesity: the Phase 3 GLORY-2 trial — Innovent Biologics investigators . The Lancet (2025)
- Mazdutide versus semaglutide in Chinese adults with Type 2 Diabetes: the Phase 3 DREAMS-3 head-to-head trial — Innovent Biologics investigators . Diabetes Care (2025)
- Safety and efficacy of mazdutide in Chinese overweight adults or adults with obesity: a randomised, double-blind, placebo-controlled phase 2 trial — Innovent Biologics investigators . The Lancet Diabetes & Endocrinology (2023) PMID: 38092790
- Mazdutide in Type 2 Diabetes: a Phase 2 randomized, double-blind, placebo-controlled trial — Innovent Biologics investigators . Diabetes Care (2024)